Covered recipient · General Payments record
RODOLFO R CANIZALES-COLLAZO
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$676.01
- Reported across 23 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $290.38 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $62.22 | 3 |
| GlaxoSmithKline, LLC. | $41.57 | 2 |
| Exact Sciences Corporation | $35.74 | 2 |
| Vanda Pharmaceuticals Inc. | $31.56 | 1 |
| Novo Nordisk AS | $21.34 | 1 |
| Teva Pharmaceuticals USA, Inc. | $18.80 | 1 |
| Nevro Corp. | $16.81 | 1 |
| Sumitomo Pharma America, Inc. | $16.42 | 1 |
| DEXCOM, INC. | $16.33 | 1 |
| Medtronic, Inc. | $15.20 | 1 |
| Antares Pharma, Inc. | $14.39 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Antares Pharma, Inc. | $14.39 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146451997 | CMS |
| Dexcom, Inc. | $16.33 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153332185 | CMS |
| Exact Sciences Corporation | $16.00 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114544706 | CMS |
| Exact Sciences Corporation | $19.74 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114544710 | CMS |
| GlaxoSmithKline, LLC. | $18.84 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116483461 | CMS |
| GlaxoSmithKline, LLC. | $22.73 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116291791 | CMS |
| Lilly USA, LLC | $24.57 | 08/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135400067 | CMS |
| Lilly USA, LLC | $19.58 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135373106 | CMS |
| Lilly USA, LLC | $18.07 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135357480 | CMS |
| Medtronic, Inc. | $15.20 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117128127 | CMS |
| Nevro Corp. | $16.81 | 08/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130777613 | CMS |
| Novo Nordisk Inc | $21.34 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097271720 | CMS |
| Sumitomo Pharma America, Inc. | $16.42 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148834891 | CMS |
| Teva Pharmaceuticals USA, Inc. | $18.80 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151582477 | CMS |
| Vanda Pharmaceuticals Inc. | $31.56 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133898725 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.